Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Frataxin is a protein encoded by the FXN gene. It promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe2+ to proteins involved in these pathways. It plays a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe2+ to Fe3.
The Frataxin Mitochondrial – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Frataxin Mitochondrial, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Frataxin Mitochondrial and features dormant and discontinued projects.
Key Therapy Areas in the Frataxin Mitochondrial Pipeline Drugs Market
In the Frataxin Mitochondrial pipeline drugs market the key therapy areas are Central Nervous System, and Cardiovascular. Central Nervous System has the highest number of pipeline products.
Frataxin Mitochondrial Drugs Market, by Therapy Areas
For more therapy area insights, download a free report sample
Key MoA in the Frataxin Mitochondrial Pipeline Drugs Market
Frataxin Mitochondrial Activator has the highest number of pipeline products followed by Frataxin Mitochondrial Replacement.
Frataxin Mitochondrial Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Frataxin Mitochondrial Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Frataxin Mitochondrial pipeline drugs market are intravenous, oral, and parenteral.
Key Molecule Types in the Frataxin Mitochondrial Pipeline Drugs Market
The key molecule types in the Frataxin Mitochondrial pipeline drugs market are Gene Therapy, Small Molecule, Recombinant Protein, Gene-Modified Cell Therapy, and Synthetic Peptide.
Frataxin Mitochondrial Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Frataxin Mitochondrial Pipeline Drugs Market
The major companies in the Frataxin Mitochondrial pipeline drugs market are Jupiter Neurosciences Inc, AavantiBio Inc, Anima Biotech Inc, Astellas Pharma Inc, Biointaxis SL, Cellivery Therapeutics Inc, CRISPR Therapeutics AG, Design Therapeutics Inc, Fratagene Therapeutics Srl, and Fulcrum Therapeutics Inc.
Frataxin Mitochondrial Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Frataxin Mitochondrial Pipeline Drugs Market Overview
| Key Therapy Areas | Central Nervous System, and Cardiovascular |
| Key Mechanisms of action | Frataxin Mitochondrial Activator, Frataxin Mitochondrial Replacement |
| Key Routes of Administration | Intravenous, Oral, and Parenteral |
| Key molecule types | Gene Therapy, Small Molecule, Recombinant Protein, Gene-Modified Cell Therapy, and Synthetic Peptide |
| Major companies | Jupiter Neurosciences Inc, AavantiBio Inc, Anima Biotech Inc, Astellas Pharma Inc, Biointaxis SL, Cellivery Therapeutics Inc, CRISPR Therapeutics AG, Design Therapeutics Inc, Fratagene Therapeutics Srl, and Fulcrum Therapeutics Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Frataxin Mitochondrial
- The pipeline guide reviews pipeline therapeutics for Frataxin Mitochondrial by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Frataxin Mitochondrial therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Frataxin Mitochondrial therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Frataxin Mitochondrial
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Frataxin Mitochondrial
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Frataxin Mitochondrial pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Anima Biotech Inc
Astellas Pharma Inc
Biointaxis SL
Cellivery Therapeutics Inc
CRISPR Therapeutics AG
Design Therapeutics Inc
Fratagene Therapeutics Srl
Fulcrum Therapeutics Inc
Jupiter Neurosciences Inc
Lacerta Therapeutics Inc
LEXEO Therapeutics LLC
Novartis Gene Therapies
PTC Therapeutics Inc
Voyager Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the Frataxin Mitochondrial pipeline drugs market?
In the Frataxin Mitochondrial pipeline drugs market, the key therapy areas are Central Nervous System, and Cardiovascular.
-
What are the key mechanisms of action in the Frataxin Mitochondrial pipeline drugs market?
In the Frataxin Mitochondrial pipeline drugs market the key mechanisms of action are Frataxin Mitochondrial Activator, and Frataxin Mitochondrial Replacement.
-
What are the key routes of administration in the Frataxin Mitochondrial pipeline drugs market?
The key routes of administration in the Frataxin Mitochondrial pipeline drugs market are intravenous, oral, and parenteral.
-
What are the key molecule types in the Frataxin Mitochondrial pipeline drugs market?
The key molecule types in the Frataxin Mitochondrial pipeline drugs market are Gene Therapy, Small Molecule, Recombinant Protein, Gene-Modified Cell Therapy, and Synthetic Peptide.
-
What are the major companies in the Frataxin Mitochondrial pipeline drugs market?
In the Frataxin Mitochondrial pipeline drugs market the major companies are Jupiter Neurosciences Inc, AavantiBio Inc, Anima Biotech Inc, Astellas Pharma Inc, Biointaxis SL, Cellivery Therapeutics Inc, CRISPR Therapeutics AG, Design Therapeutics Inc, Fratagene Therapeutics Srl, and Fulcrum Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Other Diseases reports